Here are relevant reports on : microbiome-therapeutics-market
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
The global Human Microbiome Manufacturing Services market, valued at US$0.09 billion in 2024, stood at US$0.11 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2031, culminating in a forecasted valuation of US$0.27 billion by the end of the period. Growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
The global microbiome diagnostics market, valued at US$126 million in 2022, stood at US$146 million in 2023 and is projected to advance at a resilient CAGR of 15.5% from 2023 to 2028, culminating in a forecasted valuation of US$300 million by the end of the period. Market growth is driven by the rising incidence of chronic diseases, collaborative efforts between microbiome industry and academic institutes, and growing demand of personalized medicine.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Microbiome Sequencing Services Market by Service (Sample Preparation, Sequencing, Library Preparation), Type (Amplicon Sequencing, Whole Genome Sequencing), Technology (Sequencing by Synthesis, Nanopore Sequencing), End User - Global Forecast to 2028
The global microbiome sequencing services market, valued at US$250 million in 2022, stood at US$284 million in 2023 and is projected to advance at a resilient CAGR of 14.3% from 2023 to 2028, culminating in a forecasted valuation of US$555 billion by the end of the period. Growth in this market is primarily driven by the increasing demand for metagenomic sequencing, the growing focus on the development of human microbiome therapeutics, and the high cost of advanced sequencing infrastructure.
- Published: May 2023
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026
The global aptamers market growth is primed to transition from $151 million in 2021 to $342 million by 2026, showcasing a strong CAGR of 17.7%. Growth of the market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: August 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
